Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
The Journal of Clinical Endocrinology & Metabolism · 21.01.2025 · 110 (Supplement_1) · S74-S87
DOI: 10.1210/clinem/dgae759 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.01.2025. Verfasst von Kyriakie Sarafoglou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics, Divisions of Pediatric Endocrinology and Genetics & Metabolism, University of Minnesota Medical School, Minneapolis, MN 55…. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
The traditional management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is difficult and often suboptimal.
Objective
To review improvements in the diagnosis and management of 21OHD.
Design
Literature review, synthesis, and authors’ experience.
Setting
United States (2 centers).
Participants
Not applicable.
Interventions
Not applicable. Main Outcomes Not applicable.
Results
The 11-oxygenated androgens are abundant in 21OHD, and their measurement might improve diagnosis and medication titration. Several new treatments are under development.
Conclusion
Circadian delivery of hydrocortisone improves disease management of 21OHD compared to conventional glucocorticoids. Glucocorticoid-sparing therapies such as crinecerfont and atumelnant offer the potential for a block-and-replace strategy, with physiologic replacement dosing of hydrocortisone. Clinical Trial Registration None.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Pediatrics, Divisions of Pediatric Endocrinology and Genetics & Metabolism, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
- Department of Experimental and Clinical Pharmacology, University of Minnesota School of Pharmacy, Minneapolis, MN 55455, USA.
- Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
- LTC Charles S. Kettles Veterans Affairs Medical Center, Ann Arbor, MI 48105, USA.
ORCID-Profile: Kyriakie Sarafoglou, Richard J Auchus
Zitieren
APA
Sarafoglou, K., & Auchus, R. J. (2025). Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism, 110(Supplement_1), S74-S87. https://doi.org/10.1210/clinem/dgae759
Vancouver
Sarafoglou K, Auchus RJ. Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2025;110(Supplement_1):S74-S87. doi:10.1210/clinem/dgae759
BibTeX
@article{Sarafoglou2025,
author = {Sarafoglou, Kyriakie and Auchus, Richard J},
title = {Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {Supplement_1},
pages = {S74--S87},
doi = {10.1210/clinem/dgae759}
}
EUVIMED